Moderna Stock Is Top Performer in S&P 500 Tuesday After Miserable 2023. Why This Year Could Be Better.
Share
Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
Energy Transfer Continues to Steadily Put More Cash into Its Investors’ Pockets
Wall Street braces for oil refiners’ lower Q4 earnings, tariff plans
Microsoft’s cloud growth in focus as doubts grow over AI spending
Moderna Stock Is Top Performer in S&P 500 Tuesday After Miserable 2023. Why This Year Could Be Better.
Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
View Options
Source link
Energy Transfer Continues to Steadily Put More Cash into Its Investors’ Pockets
Wall Street braces for oil refiners’ lower Q4 earnings, tariff plans
Microsoft’s cloud growth in focus as doubts grow over AI spending
TESTEX, FutureWear launch EU sustainability rules certification